Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial

Andreas Hochhaus, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane Apperley, H. Jean Khoury, Moshe Talpaz, John F. DiPersio, Daniel DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C Muller, Carlo Gambacorti-Passerini, Stephane Wong, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G Haluska, Francois Guilhot, Michael W. Deininger, Timothy P. Hughes, John M Goldman, Neil Shah, Hagop M. Kantarjian, Jorge E. Cortes and The PACE Study Group

Article Figures & Data


  • Molecular response in peripheral bloodCP-CMLa,bAP-CMLa
    R/I N=203T315I N=64R/I N=65T315I N=18
    • a Excludes 3 CP-CML and 2 AP-CML patients post-imatinib and without T315I

    • b The MMR rate in CP-CML patients previously treated with dasatinib or nilotinib was 79/256 (31%)